2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

Beyond Traditional Chemotherapy: New Directions in Lymphoma and CLL

Program: Press Program Presentations
Wednesday, December 9, 2026
11:00 a.m. - 12:00 p.m.
ASH Virtual Platform
PAPER

Abstract 0920: Results from the Phase 3 LOTIS‑5 study: Efficacy and safety of loncastuximab tesirine plus rituximab vs immunochemotherapy (R-GemOx) in patients with relapsed or refractory DLBCL

Mehdi Hamadani, MD
Mehdi Hamadani, MD: AstraZeneca - Consultancy (Includes expert testimony); ADC Therapeutics - Research Funding; ADC Therapeutics - Consultancy (Includes expert testimony); Astellas Pharma - Research Funding; Genmab - Consultancy (Includes expert testimony); Caribou - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Kite, a Gilead Company - Consultancy (Includes expert testimony); Omeros - Consultancy (Includes expert testimony); Spectrum Pharmaceuticals - Research Funding; Myeloid Therapeutics - Consultancy (Includes expert testimony); DMC: Inc - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Takeda Pharmaceutical Company - Research Funding; CRISPR - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony)